Matinas BioPharma

MTNB · Nasdaq · United States

Share price · MTNB

$0.91+0.71 (+346.74%) 3M

close as of 2026-11-18 · 24h delayed · vol 6K (0.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MTNB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Sep 2026+1481.2%
  2. 20 Aug 2026-24.3%

    Nothing announced by MTNB that day or the session before.

  3. 27 Jul 2026+37.5%
  4. 14 Jul 2026-27.1%
  5. 13 Jul 2026-36.4%
  6. 10 Jul 2026+20.4%

    Nothing announced by MTNB that day or the session before.

  7. 18 Jun 2026-14.9%

    Nothing announced by MTNB that day or the session before.

  8. 20 May 2026+14.5%

    Nothing announced by MTNB that day or the session before.

  9. 23 Apr 2026+10.2%

    Nothing announced by MTNB that day or the session before.

  10. 31 Mar 2026-11.8%

    Nothing announced by MTNB that day or the session before.

Share of unusual movement by asset

For each asset, the share of MTNB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Amphotericin B (MAT2203)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—99%
Sessions with no dated event—1%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Ergosterol (fungal cell membrane)Small molecule
Cryptococcal Meningitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
November 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-11-23 · Fiscal period ending 2026-09-30
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 July 2026Licensing dealMAT2203Matinas agrees to sell the MAT2203 subsidiary to Azurity
Matinas BioPharma; Azurity Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2——$0.8M$1.3M-$1.8M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1——$2.4M$1.9M-$1.6M operating cash flowreport ↗
2025-Q3——$5.4M$1.5M-$1.5M operating cash flowreport ↗
2025-Q2——$6.5M$5.3M-$2.0M operating cash flowreport ↗
2025-Q1—$0.1M$6.9M$1.7M-$2.0M operating cash flowreport ↗
2024-Q3—$2.2M$10M+ $0.5M short-term inv.$4.3M-$3.5M operating cash flowreport ↗
2024-Q2—$3.4M$4.2M+ $10M short-term inv.$5.7M-$3.1M operating cash flowreport ↗
2024-Q1—$3.5M$1.1M+ $7.0M short-term inv.$5.8M-$5.8M operating cash flowreport ↗
2023-Q3—$3.3M$6.4M+ $12M short-term inv.$6.1M-$4.4M operating cash flowreport ↗
2023-Q2—$3.6M$9.7M+ $13M short-term inv.$6.1M-$2.2M operating cash flowreport ↗
2023-Q1$1.1M$4.0M$5.7M+ $19M short-term inv.$5.5M-$4.1M operating cash flowreport ↗
2022-Q3$1.1M$3.7M$11M+ $22M short-term inv.$5.5M-$5.0M operating cash flowreport ↗
2022-Q2$1.1M$4.1M$10M+ $28M short-term inv.$5.9M-$5.1M operating cash flowreport ↗
2022-Q1—$5.0M$19M+ $25M short-term inv.$6.0M-$4.8M operating cash flowreport ↗
2021-Q3—$4.6M$25M+ $29M short-term inv.$6.8M-$5.8M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$0.1M$4.0M$2.6M-$7.0M operating cash flowreport ↗

For fiscal year 2025, Matinas BioPharma did not disclose revenue. R&D spend was $0.09M, down 99.2% YoY. Cash and equivalents were $4M, with a reported net loss of $10.34M and a quarterly net burn of $10.35M.

Matinas is a clinical-stage biopharmaceutical company focused on its lipid nanocrystal platform and lead candidate MAT2203. Following an 80% workforce reduction in late October 2024, the company paused further clinical development and is seeking partners for MAT2203; it has noted that a partnership or additional capital would be required before commencing the planned Phase 3 ORALTO trial. Key disclosed events include continued FDA engagement, support for the compassionate use program, and 2025 financing activity, including a February 2025 securities purchase agreement with gross proceeds of $3.3M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$11M$7.3M$6.1M-$16M operating cash flowreport ↗
2023-FY$1.1M$14M$4.8M+ $9.0M short-term inv.$5.7M-$15M operating cash flowreport ↗
2022-FY$3.2M$17M$6.8M+ $22M short-term inv.$5.3M-$19M operating cash flowreport ↗
2021-FY<$0.1M$15M$21M+ $29M short-term inv.$5.8M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06D An Evelyn · directorAward / grant (derivative)5,000——Form 4
2026-11-06NEUGEBOREN EDWARD · directorAward / grant (derivative)5,000——Form 4
2026-11-06Murphy Keith · directorAward / grant (derivative)5,000——Form 4
2026-11-06NEUGEBOREN EDWARD · directorAward / grant (derivative)5,000——Form 4
2026-11-06D An Evelyn · directorAward / grant (derivative)5,000——Form 4
2026-11-06Murphy Keith · directorAward / grant (derivative)5,000——Form 4
2026-07-10STERN ADAM K · 10% ownerOption exercise344,710$0.35$121KForm 4
2026-07-10STERN ADAM K · 10% ownerOption exercise630,335$0.35$221KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 28 reporting institutions held 0.4M shares ($177K, 2.4% of shares outstanding).

#InstitutionSharesValue
1GEODE CAPITAL MANAGEMENT, LLC65,170$33K
2CITADEL ADVISORS LLC51,698$26K
3BlackRock, Inc.49,650$25K
4VANGUARD CAPITAL MANAGEMENT LLC40,110$20K
5Holos Integrated Wealth LLC32,480$16K
6RENAISSANCE TECHNOLOGIES LLC28,570$14K
7XTX Topco Ltd20,706$10K
8VANGUARD FIDUCIARY TRUST CO18,277$9K
9STATE STREET CORP15,322$8K
10SUSQUEHANNA INTERNATIONAL GROUP, LLP14,328$7K
11Sargent Investment Group, LLC12,720$6K
12Tower Research Capital LLC (TRC)2,853$1K
13Vanguard Global Advisers, LLC1,338$669
14MORGAN STANLEY344$172
15Costello Asset Management, INC200$100